Search website

If you cannot find, what you are looking for, try searching for it below or visit our FAQ-page.

Close

2018.10.15

Survey Results on Patients’ Preference for Oral Formulations in Ulcerative Colitis Published

A paper titled “Patients’ preference and physicians perceptions of patients’ preference for oral pharmaceutical formulations: results from a real life survey” has been published in Inflammatory Intestinal Diseases.

The full publication can be accessed online at bit.ly/2NH9Vao

The paper reviews results from the exploratory survey aiming at understanding the patients’ preference for oral formulations, what triggers this preference and how it is perceived by gastroenterologists (GEs). Data on this topic are still limited. The study, sponsored by Tillotts, involved 380 patients with mild to moderate ulcerative colitis (UC) and 159 GEs in France, Germany, Spain and the United Kingdom during August and September 2017.

Results highlight a discrepancy between patients’ preference and GEs’ preference perception for oral formulation. In fact, 67% of interviewed patients prefer tablet formulations over granules while GEs estimate patients’ preference to be 49%. Moreover, patients’ preference appears to be driven by factors such as appearance (format, shape, size and colour – 44%), number of units per administration (39%) and number of administrations per day (16%). GEs, on the other hand, consider the number of administrations per day (55%), the number of units per day (26%) and tablet size (19%) as key factors when selecting a treatment.

To conclude, the paper suggests that – when possible – prescribing the patient’s preferred formulation may result in a higher adherence to medication and therefore a lower risk of symptomatic relapse and lower healthcare costs.

About UC

UC is an inflammatory bowel disease that involves chronic inflammation of the lining of the large bowel. Unlike Crohn’s disease, which can occur anywhere along the digestive tract, UC only affects the colon and rectum. UC causes swelling of the intestinal wall, in addition to ulceration of the large intestine. Symptoms vary, but often include abdominal pain and diarrhoea. UC is a chronic debilitating disease that may lead to life-threatening complications. Low adherence to medication is associated with a high risk of symptomatic relapse1,2, decreased quality of life3 and increased healthcare costs4.

To learn more about UC visit our website here.

References:

  1. Khan N., et al., Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans’ affairs healthcare system. Alimentary pharmacology & therapeutics, 2012. 36(8): p. 755-64.
  2. Kane S., et al., Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med, 2003. 114(1): p. 39-43.
  3. Kane S.V., Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther, 2006. 23(5): p. 577-85.
  4. Kane S., et al., Compliance with 5-ASA products is associated with decreased medical costs. Am J Gastroenterol 2006. 101(Suppl): p. 436.